Cite
Kellner C, Günther A, Humpe A, et al. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology. 2015;5(1):e1058459doi: 10.1080/2162402X.2015.1058459.
Kellner, C., Günther, A., Humpe, A., Repp, R., Klausz, K., Derer, S., Valerius, T., Ritgen, M., Brüggemann, M., van de Winkel, J. G., Parren, P. W., Kneba, M., Gramatzki, M., & Peipp, M. (2016). Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology, 5(1), e1058459. https://doi.org/10.1080/2162402X.2015.1058459
Kellner, Christian, et al. "Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30." Oncoimmunology vol. 5,1 (2016): e1058459. doi: https://doi.org/10.1080/2162402X.2015.1058459
Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology. 2015 Jun 05;5(1):e1058459. doi: 10.1080/2162402X.2015.1058459. eCollection 2016. PMID: 26942070; PMCID: PMC4760288.
Copy
Download .nbib